Spherix to Get Patent on Use of Tagatose as Drug to Improve Fertility

Apr 26, 2001, 01:00 ET from Spherix (Biospherics Incorporated)

    BELTSVILLE, Md., April 26 /PRNewswire/ -- Spherix (Biospherics
 Incorporated)(Nasdaq:   BINC), Beltsville, Maryland, today announced that it
 received notice that it will be awarded a U.S. patent on the use of tagatose
 as a drug to improve fertility, increase the health and number of live births
 in humans and animals, and help control excessive food intake by pregnant
 females.
     Various dose levels were administered to female and male rats and their
 food consumption, reproductive performance and fetal development were studied.
 No toxic effects were observed at any dose level.  However, high dose rates
 resulted in a greater number of pregnancies from matings by tagatose-eating
 animals compared to the number of pregnancies from an equal number of matings
 by control animals not fed tagatose.  Furthermore, the tagatose-fed animals
 produced a higher percentage of live fetuses, and their fetuses were heavier,
 although within the desired range, even though their food intake was reduced
 compared to the control animals receiving no tagatose.  This last observation
 enhances the health of the mothers and offspring alike.
     Inventor of the method, Dr. Gilbert V. Levin, said, "With the discovery of
 yet another potentially major health use of our product, tagatose is truly
 proving to be 'Nature's Best Sugar.'"  The fact that these effects were not
 observed at dose levels that consumers will get from eating tagatose in food
 products will make the medical use, which would be under a physician's
 control, easy to distinguish from food use of the product.   Spherix retains
 all rights to tagatose for non-food uses.  Levin pointed out that, "These
 preliminary results mark only the beginning of the development of a tagatose-
 based drug to treat problems of fertility, birthweight and excessive maternal
 food intake.  Drug development is a very long and expensive process.  However,
 with several important tagatose drug uses having now been patented by us, it
 is my hope that a large pharmaceutical company may become interested in taking
 on this development.  It's a whole new ball game for the uses of tagatose that
 we have reserved for Spherix."
     Tagatose was found to be GRAS under U.S. FDA regulations for use in foods
 and beverages on April 11, 2001 (Spherix News Release, April 11, 2001).  GRAS
 determination for use of the product as a sweetener in drugs, toothpaste,
 mouthwash and other cosmetic products was achieved in 2000.
 
     Certain statements contained herein are "forward looking" statements as
 defined in the Private Securities Litigation Reform Act of 1995.  Because such
 statements include risks and uncertainties, actual results may differ
 materially from those expressed or implied.  Factors that could cause actual
 results to differ materially from those expressed or implied include, but are
 not limited to, those discussed in filings by the Company with the Securities
 and Exchange Commission, including the filing on Form 8-K made on March 3,
 1999.
 
     Under its motto, "A World of Solutions," Spherix's mission is to create
 value and increase shareholder wealth through innovations that benefit our
 clients and the human condition.  Spherix offers innovations in information
 technology, knowledge management, and biotechnology.
     Our Internet address is http://www.spherixinc.com .
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X94443479
 
 

SOURCE Spherix (Biospherics Incorporated)
    BELTSVILLE, Md., April 26 /PRNewswire/ -- Spherix (Biospherics
 Incorporated)(Nasdaq:   BINC), Beltsville, Maryland, today announced that it
 received notice that it will be awarded a U.S. patent on the use of tagatose
 as a drug to improve fertility, increase the health and number of live births
 in humans and animals, and help control excessive food intake by pregnant
 females.
     Various dose levels were administered to female and male rats and their
 food consumption, reproductive performance and fetal development were studied.
 No toxic effects were observed at any dose level.  However, high dose rates
 resulted in a greater number of pregnancies from matings by tagatose-eating
 animals compared to the number of pregnancies from an equal number of matings
 by control animals not fed tagatose.  Furthermore, the tagatose-fed animals
 produced a higher percentage of live fetuses, and their fetuses were heavier,
 although within the desired range, even though their food intake was reduced
 compared to the control animals receiving no tagatose.  This last observation
 enhances the health of the mothers and offspring alike.
     Inventor of the method, Dr. Gilbert V. Levin, said, "With the discovery of
 yet another potentially major health use of our product, tagatose is truly
 proving to be 'Nature's Best Sugar.'"  The fact that these effects were not
 observed at dose levels that consumers will get from eating tagatose in food
 products will make the medical use, which would be under a physician's
 control, easy to distinguish from food use of the product.   Spherix retains
 all rights to tagatose for non-food uses.  Levin pointed out that, "These
 preliminary results mark only the beginning of the development of a tagatose-
 based drug to treat problems of fertility, birthweight and excessive maternal
 food intake.  Drug development is a very long and expensive process.  However,
 with several important tagatose drug uses having now been patented by us, it
 is my hope that a large pharmaceutical company may become interested in taking
 on this development.  It's a whole new ball game for the uses of tagatose that
 we have reserved for Spherix."
     Tagatose was found to be GRAS under U.S. FDA regulations for use in foods
 and beverages on April 11, 2001 (Spherix News Release, April 11, 2001).  GRAS
 determination for use of the product as a sweetener in drugs, toothpaste,
 mouthwash and other cosmetic products was achieved in 2000.
 
     Certain statements contained herein are "forward looking" statements as
 defined in the Private Securities Litigation Reform Act of 1995.  Because such
 statements include risks and uncertainties, actual results may differ
 materially from those expressed or implied.  Factors that could cause actual
 results to differ materially from those expressed or implied include, but are
 not limited to, those discussed in filings by the Company with the Securities
 and Exchange Commission, including the filing on Form 8-K made on March 3,
 1999.
 
     Under its motto, "A World of Solutions," Spherix's mission is to create
 value and increase shareholder wealth through innovations that benefit our
 clients and the human condition.  Spherix offers innovations in information
 technology, knowledge management, and biotechnology.
     Our Internet address is http://www.spherixinc.com .
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X94443479
 
 SOURCE  Spherix (Biospherics Incorporated)